←
Clinical Breast Cancer131 posts
Clinical Breast Cancer avatar

Clinical Breast Cancer

@CBCjournal

Official account of CBC, a journal publishing 8 issues/year on various aspects of clinical & translational breast cancer research. IF 3.225 | RTs ≠ endorsement.

◷ Joined March 2022▧ 19 Photos and videos
Hao Yin avatar
⟳ Clinical Breast Cancer retweeted
Hao Yin@HaoYin20·Jan 31

#MetaplasticBreastCancer Spindle cell/Sarcomatous histologic type N=36 is associated with reduced 3-/5-yr Recurrence-free survival & Overall survival vs other histologic types N=70 In this cohort, MpBC N=106 vs non-Mp TNBC N=106 have similar survival Discussion contains an important summary of previous studies on MpBC prognosis. @CBCjournal 2025 clinical-breast-cancer.com/a…

Post attachment
Clinical Breast Cancer avatar
Clinical Breast Cancer@CBCjournal·20 Oct 2025

Is breast-conserving therapy (BCT) safe for multifocal/multicentric breast cancer (MF/MCBC)? 🔹Meta-analysis (28,589 pts) 🔹 MF/MCBC had higher LR vs unifocal disease 🔹 LR rates comparable btw BCT & mastectomy 🔹 DFS & OS outcomes favorable #bcsm clinical-breast-cancer.com/a…

Seamus O’Reilly MD PhD avatar
⟳ Clinical Breast Cancer retweeted
Seamus O’Reilly MD PhD@Seamusoreilly18·6 Oct 2025

Solution 🌳of Sustainability for Breast Cancer Care 👇 Grateful to ✍️ co- authors for their insights

Post attachmentPost attachmentPost attachment

Climate change is the greatest threat to human health—and it directly impacts BC care. This review maps intersections between breast cancer care & planetary health and proposes a solution tree for sustainable, low-carbon practice. #bcsm @Seamusoreilly18 sciencedirect.com/science/ar…

Clinical Breast Cancer avatar
Clinical Breast Cancer@CBCjournal·22 Sep 2025

Black women face higher breast cancer mortality despite similar incidence to White women. 🧬 Universal genetic counseling/testing could aid earlier risk identification ⚡ Higher TNBC rates & earlier onset already meet NCCN criteria #bcsm @sofiamerajver clinical-breast-cancer.com/a…

Clinical Breast Cancer avatar
Clinical Breast Cancer@CBCjournal·8 Sep 2025

💡 In HER2+ breast cancer patients who achieve pCR after neoadjuvant chemo + trastuzumab/pertuzumab (TP), adjuvant therapy choice may not impact outcomes. 👉 3-yr RFS: 94.2% (TP) vs 95.6% (T) 👉 No differences in brain mets or survival #bcsm #CBCjournal clinical-breast-cancer.com/a…

Clinical Breast Cancer avatar
Clinical Breast Cancer@CBCjournal·21 Apr 2025

Radiation omission in pts w/ early BC is a dynamically changing paradigm. Individualizing treatment is paramount and understanding an individual pt's goals of treatments and values is key. Read more 👇 #bcsm @RoswellPark @si_fkf @MFarrugiaXRT @CShahMD clinical-breast-cancer.com/a…